News

Deal Announcements

Centrexion Therapeutics Nets New Debt

Tuesday, April 19, 2016 5:40:00 AM PDT | VentureDeal


Baltimore, Maryland  --  Biotechnology company Centrexion Therapeutics has received $6.9 million in new debt venture capital, according to an SEC regulatory filing.

Centrexion is developing a pipeline of non-opioid treatments for chronic pain.

Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.

A total of 21 investors participated in the offering.

CEO Jeffrey Kindler has been with the firm since 2013.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1